Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Shattuck Labs, Inc.NASDAQ: STTK
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $1M. Over 3 fiscal years it compounded at +15.3% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $100K (-90.0%) for the fiscal year ending Dec 2026, a slowdown from the -82.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $0— QoQ
- Last fiscal yearDec 2025
- $1M-82.5% YoY
- LTMMar 2026
- $1M-78.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -82.5% | -90.0% | -7.5 pp |
| 3-year CAGR | +15.3% | -41.5% | -56.8 pp |
| 5-year CAGR | -8.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 1M USD
- Year-over-year change
- -82.5%
- 4-year CAGR
- -57.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1M | -82.5% |
| FY2024 | 2024-12-31 | 5.72M | +245.3% |
| FY2023 | 2023-12-31 | 1.66M | +154.1% |
| FY2022 | 2022-12-31 | 652K | -97.8% |
| FY2021 | 2021-12-31 | 30.02M | — |
Revenue vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -78.3% is the 3rd highest of 5, against a peer median of -51.2%.
- Over three fiscal years its annual growth of +15.3% compares with a peer median of +212.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $378.98M USD | +51.3% | — | |
| LTM Mar 2026 | $227.18M USD | -2.4% | +0.0% | |
| LTM Mar 2026 | $11.88M USD | — | +424.9% | |
| LTM Mar 2026 | $1M USD | -78.3% | +15.3% | |
| LTM Sep 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
| LTM Mar 2026 | $0 USD | — | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥0 CNY | -100.0% | — |
| LTM Jun 2026 | -$4.85M USD | — | — | |
| Peer median (excluding STTK) | — | -51.2% | +212.5% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Cost of Revenue | 1.38M | 82.2M | 4.04M | 4.89M | 0 |
| Gross Profit | 28.64M | (81.55M) | (2.39M) | 827K | 1M |
| Gross Margin | 95.4% | -12507.2% | -143.9% | 14.5% | 100.0% |
| Research & Development | 56.56M | 82.9M | 74.31M | 67.21M | 35.27M |
| Selling, General & Admin | 18.72M | 19.68M | 19.3M | 19.08M | 17.24M |
| Operating Expenses | 73.91M | 21.78M | 89.57M | 81.39M | 52.51M |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| EBITDA | (43.59M) | (98.87M) | (83.26M) | (71.58M) | (45.12M) |
| EBITDA Margin | -145.2% | -15164.4% | -5024.5% | -1251.2% | -4512.1% |
| Operating Income | (45.27M) | (103.33M) | (91.96M) | (80.57M) | (51.51M) |
| Operating Margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Interest Income | 625K | 1.59M | 4.67M | 5.17M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 295K | 1.38M | 4.66M | 5.16M | 2.7M |
| Income Before Tax | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Pre-Tax Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Net Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| EPS (Basic) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| EPS (Diluted) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| Weighted Avg Shares | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
| Weighted Avg Shares (Diluted) | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.